Advocacy
Make your voice heard. Learn about PDAB legislation and implementation processes across the country.
Legislation
Illinois: HB 1443 / SB 66
Establishes the Health Care Availability and Access Board
HB 1443
1/17/25 – Introduced
SB 66
1/13/25 – Introduced and Referred to Committee on Assignments.
Iowa: SF 264
Creates a Prescription Drug Affordability Board.
SF 264
2/11/25 – Introduced
3/7/25 – Committee deadline – no action taken
Kansas: SB 212
Establishes a Prescription Drug Affordability Board
2/6/25 – Referred to Committee on Financial Institutions and Insurance
Maine: LD 697
Directs the Prescription Drug Affordability to assess strategies, including upper payment limits and reference-based pricing, to lower prescription drug costs.
2/22/25 – Referred to Committee on Health Coverage, Insurance and Financial Services
Maryland: HB424 / SB357
Requiring the Prescription Drug Affordability Board, under certain circumstances, to establish a process for setting upper payment limits for all purchases and payor reimbursements of prescription drug products in the State that the Board determines have led or will lead to affordability challenges.
HB 424
1/16/25 – Referred to Health and Government Operations Committee
SB 357
1/16/25 – Referred to Finance Committee
Michigan: SB 3
Prescription Drug Cost and Affordability Review Act
Establishes a Prescription Drug Affordability Board.
1/8/25 – Introduced and Referred to Committee on Finance, Insurance, and Consumer Protection
Nevada: AB 259
Implements reference pricing for certain prescription drugs.
2/19/25 – Introduced and Referred to Committee on Commerce and Labor
Rhode Island: S0468 / H5860
Implements reference pricing for certain prescription drugs.
S0468
2/26/25 – Introduced and Referred to Health and Human Services Committee
3/20/25 – Committee recommends measure be held for further study
H5860
2/28/25 – Introduced and Referred to Health and Human Services Committee
3/6/25 – Committee recommends the bill be held for further study
Virginia: HB 1724
Establishes a Prescription Drug Affordability Board.
1/4/25 – Introduced and referred to Committee on Labor and Commerce
1/14/25 – PASSED and referred to Appropriations Committee: 12 YES – 9 NO
1/24/25 – PASSED Appropriations – Health & Human Resources Subcommittee: 5 YES – 2 NO
1/31/25 – PASSED House – 52 YES – 44 NO
2/3/25 – Referred to Senate Committee on Commerce and Labor
2/10/25 – PASSED Senate Committee on Commerce and Labor: 10 YES – 5 NO
2/14/25 – PASSED Senate Committee on Finance and Appropriations: 10 YES – 4 NO
2/18/25 – PASSED Senate with Substitute: 26 YES – 14 NO
2/19/25 – PASSED House agreed with Senate Substitute: 52 YES – 45 NO
3/24/25 – VETOED by Governor
West Virginia: HB 2831
Establishes a Prescription Drug Affordability Board.
2/24/25 – Introduced and Referred to Health and Human Resources Committee
Implementation
Colorado Prescription Drug Affordability Board
Next Regular Meeting: April 11, 2025 – 10AM MDT
Register HERE
Previous Findings:
Trikafta – Not Unaffordable
Genvoya – Not Unaffordable
Enbrel – Unaffordable
Stelara – Unaffordable
Cosentyx – Unaffordable
The Board is considering plans for setting upper payment limits for drugs deemed unaffordable.
Maryland Prescription Drug Affordability Board
Next Board Meeting: May 19, 2025
Agenda TBD
At the May 2024 meeting, the PDAB selected six drugs for cost review:
Farxiga
Jardiance
Ozempic
Trulicity
Dupixent
Skyrizi
Data is currently being collected for the review and Board consideration is expected this fall.
Oregon Prescription Drug Affordability Board
Next Meeting: March 19 – 9AM PDT
Agenda
Register HERE
In June, the board voted to pause current assessments in order to reevaluate their process and data. Assessments are expected to resume in 2025.
Previous Findings:
Ozempic – May Cause Affordability Challenges (2/21)
Trulicity – May Cause Affordability Challenges (2/21)
Shingrix- Reviewed, No Motion to Add to List of Drugs That May Cause Affordability Challenges (2/21)
Inflectra – Removed from Affordability Review (5/15)
Skyrizi – Removed from Affordability Review (5/15)
© 2024 Value of Care Coalition
Washington, DC 20006